RU2008123811A - Хиназолины, используемые в качестве модуляторов потенциалзависимых ионных каналов - Google Patents
Хиназолины, используемые в качестве модуляторов потенциалзависимых ионных каналов Download PDFInfo
- Publication number
- RU2008123811A RU2008123811A RU2008123811/04A RU2008123811A RU2008123811A RU 2008123811 A RU2008123811 A RU 2008123811A RU 2008123811/04 A RU2008123811/04 A RU 2008123811/04A RU 2008123811 A RU2008123811 A RU 2008123811A RU 2008123811 A RU2008123811 A RU 2008123811A
- Authority
- RU
- Russia
- Prior art keywords
- pain
- alkyl
- compound according
- compound
- group
- Prior art date
Links
- 230000001419 dependent effect Effects 0.000 title claims 2
- 102000004310 Ion Channels Human genes 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract 49
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract 18
- 239000001257 hydrogen Substances 0.000 claims abstract 18
- 229910052717 sulfur Inorganic materials 0.000 claims abstract 18
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims abstract 14
- 229910052736 halogen Inorganic materials 0.000 claims abstract 14
- 150000002367 halogens Chemical class 0.000 claims abstract 14
- 229910052760 oxygen Inorganic materials 0.000 claims abstract 12
- 125000000217 alkyl group Chemical group 0.000 claims abstract 9
- 125000003342 alkenyl group Chemical group 0.000 claims abstract 8
- 125000005842 heteroatom Chemical group 0.000 claims abstract 8
- 125000001424 substituent group Chemical group 0.000 claims abstract 8
- 150000003839 salts Chemical class 0.000 claims abstract 6
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims abstract 3
- 150000002431 hydrogen Chemical class 0.000 claims abstract 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract 2
- 229910052698 phosphorus Inorganic materials 0.000 claims abstract 2
- 229910052708 sodium Inorganic materials 0.000 claims abstract 2
- 208000002193 Pain Diseases 0.000 claims 41
- -1 2-hydroxyphenyl Chemical group 0.000 claims 15
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 12
- KXDHJXZQYSOELW-UHFFFAOYSA-N carbonic acid monoamide Natural products NC(O)=O KXDHJXZQYSOELW-UHFFFAOYSA-N 0.000 claims 11
- 229920006395 saturated elastomer Polymers 0.000 claims 11
- KJAMZCVTJDTESW-UHFFFAOYSA-N tiracizine Chemical compound C1CC2=CC=CC=C2N(C(=O)CN(C)C)C2=CC(NC(=O)OCC)=CC=C21 KJAMZCVTJDTESW-UHFFFAOYSA-N 0.000 claims 11
- 208000004296 neuralgia Diseases 0.000 claims 8
- 208000005298 acute pain Diseases 0.000 claims 7
- 201000010099 disease Diseases 0.000 claims 7
- 238000000034 method Methods 0.000 claims 7
- 229910052757 nitrogen Inorganic materials 0.000 claims 7
- 206010019233 Headaches Diseases 0.000 claims 6
- 125000003118 aryl group Chemical group 0.000 claims 6
- 125000001072 heteroaryl group Chemical group 0.000 claims 6
- 208000021722 neuropathic pain Diseases 0.000 claims 6
- 208000000094 Chronic Pain Diseases 0.000 claims 5
- 230000001154 acute effect Effects 0.000 claims 5
- 230000001684 chronic effect Effects 0.000 claims 5
- 208000035475 disorder Diseases 0.000 claims 5
- 231100000869 headache Toxicity 0.000 claims 5
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 claims 5
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 claims 4
- AQEFLFZSWDEAIP-UHFFFAOYSA-N di-tert-butyl ether Chemical compound CC(C)(C)OC(C)(C)C AQEFLFZSWDEAIP-UHFFFAOYSA-N 0.000 claims 4
- 208000011580 syndromic disease Diseases 0.000 claims 4
- 208000005615 Interstitial Cystitis Diseases 0.000 claims 3
- 206010028836 Neck pain Diseases 0.000 claims 3
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 208000004550 Postoperative Pain Diseases 0.000 claims 3
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 3
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 3
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 3
- 230000006378 damage Effects 0.000 claims 3
- 125000000623 heterocyclic group Chemical group 0.000 claims 3
- 201000006417 multiple sclerosis Diseases 0.000 claims 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 3
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 3
- 239000001301 oxygen Chemical group 0.000 claims 3
- 239000011593 sulfur Chemical group 0.000 claims 3
- 208000009935 visceral pain Diseases 0.000 claims 3
- XTDKZSUYCXHXJM-UHFFFAOYSA-N 2-methoxyoxane Chemical compound COC1CCCCO1 XTDKZSUYCXHXJM-UHFFFAOYSA-N 0.000 claims 2
- 208000004998 Abdominal Pain Diseases 0.000 claims 2
- 208000008035 Back Pain Diseases 0.000 claims 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims 2
- 206010065390 Inflammatory pain Diseases 0.000 claims 2
- 208000019695 Migraine disease Diseases 0.000 claims 2
- 206010033645 Pancreatitis Diseases 0.000 claims 2
- 206010036376 Postherpetic Neuralgia Diseases 0.000 claims 2
- 206010059604 Radicular pain Diseases 0.000 claims 2
- 208000008765 Sciatica Diseases 0.000 claims 2
- 206010046543 Urinary incontinence Diseases 0.000 claims 2
- RDOXTESZEPMUJZ-UHFFFAOYSA-N anisole Chemical compound COC1=CC=CC=C1 RDOXTESZEPMUJZ-UHFFFAOYSA-N 0.000 claims 2
- 208000029078 coronary artery disease Diseases 0.000 claims 2
- 229910052731 fluorine Inorganic materials 0.000 claims 2
- 239000011737 fluorine Substances 0.000 claims 2
- 206010027599 migraine Diseases 0.000 claims 2
- 125000002950 monocyclic group Chemical group 0.000 claims 2
- 230000002981 neuropathic effect Effects 0.000 claims 2
- 201000001119 neuropathy Diseases 0.000 claims 2
- 230000007823 neuropathy Effects 0.000 claims 2
- 201000008482 osteoarthritis Diseases 0.000 claims 2
- UUEVFMOUBSLVJW-UHFFFAOYSA-N oxo-[[1-[2-[2-[2-[4-(oxoazaniumylmethylidene)pyridin-1-yl]ethoxy]ethoxy]ethyl]pyridin-4-ylidene]methyl]azanium;dibromide Chemical compound [Br-].[Br-].C1=CC(=C[NH+]=O)C=CN1CCOCCOCCN1C=CC(=C[NH+]=O)C=C1 UUEVFMOUBSLVJW-UHFFFAOYSA-N 0.000 claims 2
- 230000002093 peripheral effect Effects 0.000 claims 2
- 208000033808 peripheral neuropathy Diseases 0.000 claims 2
- 125000004193 piperazinyl group Chemical group 0.000 claims 2
- 125000003386 piperidinyl group Chemical group 0.000 claims 2
- ATHGHQPFGPMSJY-UHFFFAOYSA-N spermidine Chemical compound NCCCCNCCCN ATHGHQPFGPMSJY-UHFFFAOYSA-N 0.000 claims 2
- 206010044652 trigeminal neuralgia Diseases 0.000 claims 2
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N 3-methoxypyridine Chemical compound COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims 1
- BJMPSYHNUKWPGQ-UHFFFAOYSA-N 4-methoxy-1,3-benzodioxole Chemical compound COC1=CC=CC2=C1OCO2 BJMPSYHNUKWPGQ-UHFFFAOYSA-N 0.000 claims 1
- XQABVLBGNWBWIV-UHFFFAOYSA-N 4-methoxypyridine Chemical compound COC1=CC=NC=C1 XQABVLBGNWBWIV-UHFFFAOYSA-N 0.000 claims 1
- 208000019901 Anxiety disease Diseases 0.000 claims 1
- 206010003011 Appendicitis Diseases 0.000 claims 1
- 206010003591 Ataxia Diseases 0.000 claims 1
- 206010006002 Bone pain Diseases 0.000 claims 1
- 206010064012 Central pain syndrome Diseases 0.000 claims 1
- 206010008479 Chest Pain Diseases 0.000 claims 1
- CKLJMWTZIZZHCS-UHFFFAOYSA-N D-OH-Asp Natural products OC(=O)C(N)CC(O)=O CKLJMWTZIZZHCS-UHFFFAOYSA-N 0.000 claims 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 claims 1
- 201000009273 Endometriosis Diseases 0.000 claims 1
- 208000024720 Fabry Disease Diseases 0.000 claims 1
- 206010016059 Facial pain Diseases 0.000 claims 1
- 208000001640 Fibromyalgia Diseases 0.000 claims 1
- 206010019909 Hernia Diseases 0.000 claims 1
- 208000007514 Herpes zoster Diseases 0.000 claims 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 1
- 206010020853 Hypertonic bladder Diseases 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 206010024229 Leprosy Diseases 0.000 claims 1
- 208000016285 Movement disease Diseases 0.000 claims 1
- 206010028391 Musculoskeletal Pain Diseases 0.000 claims 1
- 208000030858 Myofascial Pain Syndromes Diseases 0.000 claims 1
- 206010061533 Myotonia Diseases 0.000 claims 1
- IHYJTAOFMMMOPX-LURJTMIESA-N N-acetyl-L-valine Chemical group CC(C)[C@@H](C(O)=O)NC(C)=O IHYJTAOFMMMOPX-LURJTMIESA-N 0.000 claims 1
- 206010029216 Nervousness Diseases 0.000 claims 1
- 208000005890 Neuroma Diseases 0.000 claims 1
- 208000001294 Nociceptive Pain Diseases 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 208000009722 Overactive Urinary Bladder Diseases 0.000 claims 1
- 206010033647 Pancreatitis acute Diseases 0.000 claims 1
- 208000000450 Pelvic Pain Diseases 0.000 claims 1
- 208000004983 Phantom Limb Diseases 0.000 claims 1
- 206010056238 Phantom pain Diseases 0.000 claims 1
- 206010037596 Pyelonephritis Diseases 0.000 claims 1
- 206010037779 Radiculopathy Diseases 0.000 claims 1
- 206010038419 Renal colic Diseases 0.000 claims 1
- 206010040037 Sensory neuropathy hereditary Diseases 0.000 claims 1
- 108010052164 Sodium Channels Proteins 0.000 claims 1
- 102000018674 Sodium Channels Human genes 0.000 claims 1
- 208000000491 Tendinopathy Diseases 0.000 claims 1
- 206010043255 Tendonitis Diseases 0.000 claims 1
- 208000025609 Urogenital disease Diseases 0.000 claims 1
- 230000004913 activation Effects 0.000 claims 1
- 201000003229 acute pancreatitis Diseases 0.000 claims 1
- 230000036506 anxiety Effects 0.000 claims 1
- 206010003119 arrhythmia Diseases 0.000 claims 1
- 230000006793 arrhythmia Effects 0.000 claims 1
- 206010003246 arthritis Diseases 0.000 claims 1
- 125000004429 atom Chemical group 0.000 claims 1
- 125000002619 bicyclic group Chemical group 0.000 claims 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 125000002837 carbocyclic group Chemical group 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 238000002512 chemotherapy Methods 0.000 claims 1
- 230000035606 childbirth Effects 0.000 claims 1
- 201000001352 cholecystitis Diseases 0.000 claims 1
- 208000012696 congenital leptin deficiency Diseases 0.000 claims 1
- 125000004122 cyclic group Chemical group 0.000 claims 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 206010015037 epilepsy Diseases 0.000 claims 1
- 230000001037 epileptic effect Effects 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 208000037584 hereditary sensory and autonomic neuropathy Diseases 0.000 claims 1
- 201000006847 hereditary sensory neuropathy Diseases 0.000 claims 1
- 208000012285 hip pain Diseases 0.000 claims 1
- 208000013403 hyperactivity Diseases 0.000 claims 1
- 230000002757 inflammatory effect Effects 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- 208000003243 intestinal obstruction Diseases 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 208000001022 morbid obesity Diseases 0.000 claims 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 208000015706 neuroendocrine disease Diseases 0.000 claims 1
- 208000020629 overactive bladder Diseases 0.000 claims 1
- 210000000578 peripheral nerve Anatomy 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 208000001297 phlebitis Diseases 0.000 claims 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 201000007094 prostatitis Diseases 0.000 claims 1
- 208000020016 psychiatric disease Diseases 0.000 claims 1
- 125000004076 pyridyl group Chemical group 0.000 claims 1
- 238000001959 radiotherapy Methods 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 230000028327 secretion Effects 0.000 claims 1
- 208000007056 sickle cell anemia Diseases 0.000 claims 1
- 201000009890 sinusitis Diseases 0.000 claims 1
- 239000011734 sodium Substances 0.000 claims 1
- 229940063673 spermidine Drugs 0.000 claims 1
- 210000000278 spinal cord Anatomy 0.000 claims 1
- 208000005198 spinal stenosis Diseases 0.000 claims 1
- 230000008961 swelling Effects 0.000 claims 1
- 210000001738 temporomandibular joint Anatomy 0.000 claims 1
- 201000004415 tendinitis Diseases 0.000 claims 1
- 125000000335 thiazolyl group Chemical group 0.000 claims 1
- 208000004371 toothache Diseases 0.000 claims 1
- 230000008736 traumatic injury Effects 0.000 claims 1
- 241001529453 unidentified herpesvirus Species 0.000 claims 1
- 208000026533 urinary bladder disease Diseases 0.000 claims 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 abstract 2
- 125000001931 aliphatic group Chemical group 0.000 abstract 1
- 0 C*1*CCC1 Chemical compound C*1*CCC1 0.000 description 4
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Psychiatry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Endocrinology (AREA)
- Virology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- AIDS & HIV (AREA)
- Oncology (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Dermatology (AREA)
- Immunology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US73733005P | 2005-11-14 | 2005-11-14 | |
| US60/737,330 | 2005-11-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2008123811A true RU2008123811A (ru) | 2009-12-27 |
Family
ID=38049182
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2008123811/04A RU2008123811A (ru) | 2005-11-14 | 2006-11-13 | Хиназолины, используемые в качестве модуляторов потенциалзависимых ионных каналов |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US8158637B2 (enExample) |
| EP (1) | EP1957482B1 (enExample) |
| JP (1) | JP2009515892A (enExample) |
| KR (1) | KR20080073749A (enExample) |
| CN (1) | CN101356168A (enExample) |
| AR (1) | AR057576A1 (enExample) |
| AT (1) | ATE540033T1 (enExample) |
| AU (1) | AU2006315675B2 (enExample) |
| CA (1) | CA2628650A1 (enExample) |
| ES (1) | ES2377988T3 (enExample) |
| MX (1) | MX2008006303A (enExample) |
| NO (1) | NO20082746L (enExample) |
| NZ (1) | NZ568393A (enExample) |
| RU (1) | RU2008123811A (enExample) |
| TW (1) | TW200804348A (enExample) |
| WO (1) | WO2007058989A2 (enExample) |
| ZA (1) | ZA200804043B (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CL2004000409A1 (es) | 2003-03-03 | 2005-01-07 | Vertex Pharma | Compuestos derivados de 2-(cilo sustituido)-1-(amino u oxi sustituido)-quinazolina, inhibidores de canales ionicos de sodio y calcio dependientes de voltaje; composicion farmaceutica; y uso del compuesto en el tratamiento de dolor agudo, cronico, neu |
| US7713983B2 (en) * | 2003-03-03 | 2010-05-11 | Vertex Pharmaceuticals Incorporated | Quinazolines useful as modulators of ion channels |
| US7718658B2 (en) * | 2004-09-02 | 2010-05-18 | Vertex Pharmaceuticals Incorporated | Quinazolines useful as modulators of ion channels |
| US8283354B2 (en) * | 2004-09-02 | 2012-10-09 | Vertex Pharmaceuticals Incorporated | Quinazolines useful as modulators of ion channels |
| US7928107B2 (en) | 2004-09-02 | 2011-04-19 | Vertex Pharmaceuticals Incorporated | Quinazolines useful as modulators of ion channels |
| EP1828150B1 (en) * | 2004-12-17 | 2012-03-14 | Vertex Pharmaceuticals Incorporated | Processes for producing 4-aminoquinazolines |
| MX2008006303A (es) * | 2005-11-14 | 2009-02-26 | Vertex Pharma | Quinazolinas de utilidad como moduladores de canales ionicos regulados por voltaje. |
| WO2012046132A1 (en) | 2010-10-05 | 2012-04-12 | Purdue Pharma L.P. | Quinazoline compounds as sodium channel blockers |
| KR101657616B1 (ko) * | 2013-05-24 | 2016-09-19 | 주식회사유한양행 | 피리미딘 고리를 포함하는 바이사이클릭 유도체 및 그의 제조방법 |
| EP3551188B1 (en) | 2017-10-31 | 2023-10-18 | Southern Research Institute | Substituted quinazoline sulfonamides as thioredoxin interacting protein (txnip) inhibitors |
| MA56398A (fr) * | 2019-06-27 | 2022-05-04 | Glaxosmithkline Ip Dev Ltd | Composés 2,3-dihydroquinazoline en tant qu'inhibiteurs de nav1.8 |
| TWI813493B (zh) * | 2021-07-20 | 2023-08-21 | 友達光電股份有限公司 | 顯示裝置 |
| CA3256486A1 (en) * | 2022-04-25 | 2023-11-02 | Siteone Therapeutics Inc | Bicyclic Na V1.8 Heterocyclic Amide Inhibitors for Pain Management |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FI20021314A0 (fi) * | 2002-07-03 | 2002-07-03 | Nokia Corp | Tiedonsiirtomenetelmä ja järjestely |
| CL2004000409A1 (es) | 2003-03-03 | 2005-01-07 | Vertex Pharma | Compuestos derivados de 2-(cilo sustituido)-1-(amino u oxi sustituido)-quinazolina, inhibidores de canales ionicos de sodio y calcio dependientes de voltaje; composicion farmaceutica; y uso del compuesto en el tratamiento de dolor agudo, cronico, neu |
| US7713983B2 (en) | 2003-03-03 | 2010-05-11 | Vertex Pharmaceuticals Incorporated | Quinazolines useful as modulators of ion channels |
| US7718658B2 (en) | 2004-09-02 | 2010-05-18 | Vertex Pharmaceuticals Incorporated | Quinazolines useful as modulators of ion channels |
| US7928107B2 (en) | 2004-09-02 | 2011-04-19 | Vertex Pharmaceuticals Incorporated | Quinazolines useful as modulators of ion channels |
| WO2006028904A1 (en) * | 2004-09-02 | 2006-03-16 | Vertex Pharmaceuticals Incorporated | Quinazolines useful as modulators of ion channels |
| US8283354B2 (en) | 2004-09-02 | 2012-10-09 | Vertex Pharmaceuticals Incorporated | Quinazolines useful as modulators of ion channels |
| EP1828150B1 (en) | 2004-12-17 | 2012-03-14 | Vertex Pharmaceuticals Incorporated | Processes for producing 4-aminoquinazolines |
| MX2008006303A (es) * | 2005-11-14 | 2009-02-26 | Vertex Pharma | Quinazolinas de utilidad como moduladores de canales ionicos regulados por voltaje. |
-
2006
- 2006-11-13 MX MX2008006303A patent/MX2008006303A/es not_active Application Discontinuation
- 2006-11-13 AT AT06837387T patent/ATE540033T1/de active
- 2006-11-13 JP JP2008540234A patent/JP2009515892A/ja active Pending
- 2006-11-13 CA CA002628650A patent/CA2628650A1/en not_active Abandoned
- 2006-11-13 WO PCT/US2006/043895 patent/WO2007058989A2/en not_active Ceased
- 2006-11-13 US US11/598,576 patent/US8158637B2/en not_active Expired - Fee Related
- 2006-11-13 CN CNA2006800507452A patent/CN101356168A/zh active Pending
- 2006-11-13 KR KR1020087014446A patent/KR20080073749A/ko not_active Withdrawn
- 2006-11-13 AU AU2006315675A patent/AU2006315675B2/en not_active Ceased
- 2006-11-13 ZA ZA200804043A patent/ZA200804043B/xx unknown
- 2006-11-13 NZ NZ568393A patent/NZ568393A/en not_active IP Right Cessation
- 2006-11-13 EP EP06837387A patent/EP1957482B1/en not_active Not-in-force
- 2006-11-13 ES ES06837387T patent/ES2377988T3/es active Active
- 2006-11-13 RU RU2008123811/04A patent/RU2008123811A/ru not_active Application Discontinuation
- 2006-11-14 AR ARP060104980A patent/AR057576A1/es unknown
- 2006-11-14 TW TW095142123A patent/TW200804348A/zh unknown
-
2008
- 2008-03-18 US US12/050,289 patent/US8809353B2/en active Active
- 2008-06-13 NO NO20082746A patent/NO20082746L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| JP2009515892A (ja) | 2009-04-16 |
| ATE540033T1 (de) | 2012-01-15 |
| WO2007058989A2 (en) | 2007-05-24 |
| WO2007058989A3 (en) | 2007-09-07 |
| MX2008006303A (es) | 2009-02-26 |
| ZA200804043B (en) | 2010-01-27 |
| US8809353B2 (en) | 2014-08-19 |
| US20080167305A1 (en) | 2008-07-10 |
| NZ568393A (en) | 2011-08-26 |
| EP1957482B1 (en) | 2012-01-04 |
| AU2006315675A1 (en) | 2007-05-24 |
| TW200804348A (en) | 2008-01-16 |
| CN101356168A (zh) | 2009-01-28 |
| CA2628650A1 (en) | 2007-05-24 |
| KR20080073749A (ko) | 2008-08-11 |
| NO20082746L (no) | 2008-08-08 |
| ES2377988T3 (es) | 2012-04-03 |
| US8158637B2 (en) | 2012-04-17 |
| AU2006315675B2 (en) | 2012-06-07 |
| AR057576A1 (es) | 2007-12-05 |
| US20080221137A1 (en) | 2008-09-11 |
| EP1957482A2 (en) | 2008-08-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2007111897A (ru) | Хиназолины, полезные в качестве модуляторов ионных каналов перекрестные ссылки на родственные заявки | |
| RU2008123811A (ru) | Хиназолины, используемые в качестве модуляторов потенциалзависимых ионных каналов | |
| RU2397976C2 (ru) | Производные бензамидов и гетероаренов | |
| US7718674B2 (en) | Methods of relieving neuropathic pain with the S-isomer of 2-{2[N-(2-indanyl)-N-phenylamino]ethyl}piperidine | |
| DK1140745T3 (da) | Colchinolderivater som vaskulært skadelige midler | |
| US20060079558A1 (en) | R-isomer of 2-{2[N-(2-indanyl)-N-phenylamino]ethyl}piperidine and other dermal anesthetics | |
| RU2014142795A (ru) | Некоторые химические структуры, композиции и способы | |
| RU99105119A (ru) | Производные пурина и их применение в качестве антикоагулянтов | |
| KR20170131650A (ko) | 글루타미나제 억제제의 투여 방법 | |
| RU2008130094A (ru) | Модуляторы мускариновых рецепторов | |
| RU2010100945A (ru) | Способы и композиции для стимулирования нейрогенеза и ингибирования дегенерации нейронов с использованием изотиазолопиримидинонов | |
| JP2011510965A (ja) | 高眼圧症の治療のためのジフルオロビフェニルアミド誘導体 | |
| BRPI0719061A2 (pt) | Pró-fármacos de prostaglandina | |
| KR20150046269A (ko) | 베타-클로로시클로펜탄의 친수성 에스테르 전구약물의 이용에 의한 감소된 중심 각막 비후 | |
| JP2009513707A (ja) | ジアリールウレア及び併用剤 | |
| KR970006281A (ko) | 치환된 신남산 구아니디드, 이의 제조방법, 약제 또는 진단제로서의 이의 용도 및 이를 포함하는 약제 | |
| RU2003122189A (ru) | Сульфамидотиенопиримидины | |
| RU2007112501A (ru) | Бензимидазольные производные, содержащие их композиции, их получение и применение | |
| CA1327163C (en) | Anxiolytically active piperazine derivatives | |
| JP2008542377A5 (enExample) | ||
| RU2006105634A (ru) | Производные-аминоамидов, применимые в качестве противовоспалительных агентов | |
| JP2008540665A5 (enExample) | ||
| AU2015259752B2 (en) | Reduced central corneal thickening by use of hydrophilic ester prodrugs of beta-chlorocyclopentanes | |
| US20020040162A1 (en) | Contrast media for angiography | |
| RU2006105792A (ru) | Производные 2,4 (фениламино)пиперидин-1-ил-n-фенилацетамида и родственные соединения в качестве y5 (npy5) лигандов для лечения ожирения |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA93 | Acknowledgement of application withdrawn (no request for examination) |
Effective date: 20100908 |